A5050796151- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Vitamin C and Antioxidants Research
- Heart Rate Variability and Autonomic Control
- Inflammasome and immune disorders
- Dermatologic Treatments and Research
- COVID-19 and healthcare impacts
- Drug-Induced Hepatotoxicity and Protection
- Intramuscular injections and effects
- Thermal Regulation in Medicine
- Diagnosis and Treatment of Venous Diseases
- Cardiovascular Disease and Adiposity
- Urticaria and Related Conditions
- Acne and Rosacea Treatments and Effects
- Venous Thromboembolism Diagnosis and Management
- Neurological Disorders and Treatments
- Skin Protection and Aging
Pronatura Noroeste
2025
Mexican Social Security Institute
2020-2021
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce several vascular endothelial-dependent systemic complications, and sulodexide has pleiotropic actions on the endothelium, which prove beneficial. We aimed to assess effect of when used within 3 days disease 2019 (COVID-19) clinical onset. conducted a randomized placebo-controlled outpatient trial. To be included, patients must have been at high risk for severe progression. Participants received (oral 1,000...
Introduction Persistent elevation of biomarkers associated with endothelial dysfunction in convalescent COVID-19 patients has been linked to an increased risk long-term cardiovascular complications, including long COVID syndrome. Sulodexide, known for its vascular affinity, demonstrated pleiotropic protective properties. This study aims evaluate the impact sulodexide on serum levels during phase COVID-19. Methods We conducted a double-blind, single-center, randomized, placebo-controlled...
Background: Targeting endothelial cells has been suggested for the treatment of patients with COVID-19 and sulodexide pleiotropic properties within vascular endothelium that can prove beneficial to same. We aimed evaluate effect when used in early clinical stages COVID-19. Methods: conducted a single-centre, outpatient setting, randomized controlled trial parallel-group design Mexico. Including three days symptom onset, who were at high risk severe progression due chronic comorbidities....
Abstract Background Targeting endothelial cells has been suggested for the treatment of patients with COVID-19 and sulodexide pleiotropic properties within vascular endothelium that can prove beneficial to same. We aimed evaluate effect when used in early clinical stages COVID-19. Methods conducted a single-centre, outpatient setting, randomised controlled trial parallel-group design Mexico. Including three days symptom onset, who were at high risk severe progression due chronic...
Patients with novel coronavirus disease-2019 (COVID-19), present a systemic inflammatory response vascular endothelial damage and an increased risk of thromboembolic complications. Sulodexide can help restore venous arterial glycocalyx integrity lost in certain chronic diseases, which downregulate or limit the to molecules. It has antithrombotic effect that could reduce incidence complications be beneficial these patients. We hypothesize sulodexide, instituted early symptomatic stages...